[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$nktrs Graphic $nktrs

$NKTR sees a surge in social engagement amid discussions of potential damages from LLY and positive trial results. Users are anticipating a favorable outcome for NKTR's legal claims and drug development, with SNY's market cap dropping significantly.

About $nktrs

Social media analysis of the stock ticker $nktrs.

Engagements: XX #


Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXXXX
1 Week: XXXXX -XX%
1 Month: XXXXXX -XX%
1-Year High: XXXXXX on 2025-10-06
1-Year Low: XX on 2025-07-10

Social Network X
Engagements XX

Mentions: X #


Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-09-10
1-Year Low: X on 2025-06-27

Social Network X
Mentions X

Creators: X #


Creators Line Chart
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $nktrs in the last XX hours which is no change from in the previous XX hours Daily Average: X
1-Year High: X on 2025-09-10
1-Year Low: X on 2025-06-27

The most influential creators that mention $nktrs in the last XX hours

Creator Rank Followers Posts Engagements
@A_May_MD X XXXXXX X XX

View More

Top assets mentioned In the posts about $nktrs in the last XX hours

Sanofi (SNY) Synthetify (SNY)

Top topics mentioned In the posts about $nktrs in the last XX hours

sanofi, stocks healthcare, $sny, $nktr, $122b, $snys

Top Social Posts #


Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"And one more thing - I do hear the argument "well $SNY traded down because P3 efficacy got worse compared to P2. Couldn't the same thing happen to $NKTR" Sure it could but $SNY's efficacy decayed almost entirely due to higher placebo response rates in P3 compared to P2 jumping from XX% to 19%. $NKTR's P2b pbo rate was already XX% - just X points off of where $SNY's P3 ended up. $NKTR is in a fantastic spot to be able to reproduce a P3 EASI75 delta in the same range as their P2's was. If that happens this will be a biotech "phoenix from the ashes" story of the ages Last time I'll say it. I"
X Link @A_May_MD 2025-09-04T21:29Z 17.4K followers, 40K engagements

"Final Numbers: $SNY down $12.2B $NKTR up $0.11B. $SNY lost 111x what $NKTR gained today. I'm a broken (and biased) record on $NKTR's valuation but seriously - why isn't this thing getting any respect for the size of the 2L+ atopic derm market and the P2b data they already have I feel like I'm going insane when I review all the data and market sizes here and ending up with this $700M valuation. It's similar to how I felt when I posted what I considered to be borderline mathematical proof that $ABVX was going to hit in P3 only for the stock to trade down a few cents over the next XX hours"
X Link @A_May_MD 2025-09-04T21:29Z 17.4K followers, 75.6K engagements